Related Experiment Video
Updated: Jul 7, 2026

Bladder Smooth Muscle Strip Contractility as a Method to Evaluate Lower Urinary Tract Pharmacology
Published on: August 18, 2014
Alpha1-adrenoceptor subtypes and lower urinary tract symptoms
Debra A Schwinn1, Claus G Roehrborn
1Department of Anesthesiology, University of Washington, Seattle, Washington 98195-6540, USA. dschwinn@u.washington.edu
Benign prostatic hyperplasia (BPH) causes urinary issues in aging men. Alpha(1)-adrenoceptor antagonists effectively treat these lower urinary tract symptoms (LUTS) by relaxing smooth muscle and reducing resistance.
Area of Science:
- Urology
- Pharmacology
Background:
- Benign prostatic hyperplasia (BPH) is a prevalent condition causing urinary outflow obstruction and lower urinary tract symptoms (LUTS) in aging men.
- Alpha(1)-adrenoceptor (alpha(1)AR) antagonists are a primary treatment for LUTS, offering relief by relaxing prostate smooth muscle and decreasing urethral resistance.
Purpose of the Study:
- To review recent clinical trials on alpha(1)AR antagonists for LUTS treatment.
- To explore the role of specific alpha(1)AR subtypes in managing LUTS associated with BPH.
Main Methods:
- Review of key recent clinical trials.
- Analysis of alpha(1)AR antagonist efficacy and subtype specificity.
Main Results:
- Alpha(1)AR antagonists are effective in relieving bladder LUTS symptoms.
- New insights suggest specific alpha(1)AR subtypes play a crucial role in treatment efficacy.
Conclusions:
- Alpha(1)AR antagonists remain a cornerstone therapy for BPH-related LUTS.
- Understanding alpha(1)AR subtype roles may refine treatment strategies for lower urinary tract symptoms.
Related Concept Videos
Adrenergic Receptors: ɑ Subtype
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase C—inositol-1,4,5-trisphosphate...
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...
Adrenergic Receptors: β Subtype
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors have equal affinities for...
Adrenergic Receptors (Adrenoceptors): Classification
α-Adrenoceptors
α-Adrenoceptors are classified into two main subtypes: α1 and α2. The α1 adrenoceptors, which are found on postsynaptic...
Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline moieties. Phenoxybenzamine, with a haloalkylamine...
Adrenergic Agonists: Direct-Acting Agents
These agents can be classified...
